CommentaryPolicy

Implementing Socially Responsible Licensing for Global Health: Beyond Neglected Diseases

See allHide authors and affiliations

Science Translational Medicine  29 Oct 2014:
Vol. 6, Issue 260, pp. 260cm11
DOI: 10.1126/scitranslmed.3009422

Figures

  • Fig. 1 Good grades.

    Global access policies (on a scale from 0 to 100%) versus global health innovations, with a focus on neglected diseases (on a scale from 0 to 100%), is shown for 54 North American universities. Data were compiled from (16, 17, 21).

    CREDIT: H. McDONALD/SCIENCE TRANSLATIONAL MEDICINE

Tables

  • Table 1

    Policies and practices that promote global access

    SRL• License nonexclusively• Use terms that limit geographic area or field of use so that technologies may be licensed differentially in developed and developing countries• Require licensees to further develop products or technologies for developing countries• Require licensees (exclusive or nonexclusive) to provide differential access or pricing for developing countries• Ensure licenses include a liberal reservation of rights for further noncommercial research by the originating university or all research institutions• Include Access and Benefit Sharing terms as appropriate.
    Research contracts and IP management• Promote innovation through nonenforcement of patents against other universities• Ensure the return of benefits (not necessarily monetary) to research partners in developing countries that participated in research and/or contributed resources or expertise to research• Ensure that research contracts include mechanisms to build research capacity in developing country institutions• Develop and adopt commercialization metrics that capture the social, cultural, and institutional value of research and development.
    Data sources: (2, 13, 15, 16, 19)

Stay Connected to Science Translational Medicine

Navigate This Article